
|Videos|July 31, 2020
AsclepiX lead candidate holds potential for wet AMD, DME, RVO (ASRS 2020)
Author(s)Alex Delaney-Gesing , Sheryl Stevenson
Theresa Heah, MD, provides an update on AsclepiX’s AXT107, which is derived from a cryptic peptide within collagen IV that works by activating naturally existing, homeostatic mechanisms of angiogenesis.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approves veligrotug-vvze (Lumvoa) for thyroid eye disease across active and chronic stages
2
Dry Eye Awareness Month: building a strong optometry-ophthalmology co-management model
3
FDA grants priority review to Satralizumab sBLA for thyroid eye disease
4
REGENXBIO doses first patient in NAAVIGATE, phase 2b/3 sura-vec trial for diabetic retinopathy
5
























